Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
Lock In $149
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CollPlant Biotechnologies Ltd. Sponsored ADR stock logo
CLGN
CollPlant Biotechnologies
$3.66
+1.1%		$3.61
$2.64
▼
$23.80
$6.92M1.77119,152 shs7,647 shs
Genprex stock logo
GNPX
Genprex
$1.87
-5.8%		$3.22
$1.90
▼
$222.20
$1.53M-0.99112,653 shs114,082 shs
MetaVia Inc. stock logo
MTVA
MetaVia
$1.41
+1.4%		$1.56
$0.97
▼
$14.85
$7.28M0.961.30 million shs53,453 shs
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
$1.59
-2.1%		$1.89
$1.50
▼
$13.28
$6.91M2.8659,197 shs6,040 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CollPlant Biotechnologies Ltd. Sponsored ADR stock logo
CLGN
CollPlant Biotechnologies
-3.72%-1.63%-5.97%+14.92%-83.98%
Genprex stock logo
GNPX
Genprex
-3.41%-13.54%-44.07%-74.65%-99.18%
MetaVia Inc. stock logo
MTVA
MetaVia
+3.73%+1.46%-17.26%-6.08%-86.83%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-0.61%+1.89%-5.26%-68.94%-85.84%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CollPlant Biotechnologies Ltd. Sponsored ADR stock logo
CLGN
CollPlant Biotechnologies
$3.66
+1.1%		$3.61
$2.64
▼
$23.80
$6.92M1.77119,152 shs7,647 shs
Genprex stock logo
GNPX
Genprex
$1.87
-5.8%		$3.22
$1.90
▼
$222.20
$1.53M-0.99112,653 shs114,082 shs
MetaVia Inc. stock logo
MTVA
MetaVia
$1.41
+1.4%		$1.56
$0.97
▼
$14.85
$7.28M0.961.30 million shs53,453 shs
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
$1.59
-2.1%		$1.89
$1.50
▼
$13.28
$6.91M2.8659,197 shs6,040 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CollPlant Biotechnologies Ltd. Sponsored ADR stock logo
CLGN
CollPlant Biotechnologies
-3.72%-1.63%-5.97%+14.92%-83.98%
Genprex stock logo
GNPX
Genprex
-3.41%-13.54%-44.07%-74.65%-99.18%
MetaVia Inc. stock logo
MTVA
MetaVia
+3.73%+1.46%-17.26%-6.08%-86.83%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-0.61%+1.89%-5.26%-68.94%-85.84%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CollPlant Biotechnologies Ltd. Sponsored ADR stock logo
CLGN
CollPlant Biotechnologies
1.50
Reduce$120.003,178.69% Upside
Genprex stock logo
GNPX
Genprex
1.00
SellN/AN/A
MetaVia Inc. stock logo
MTVA
MetaVia
2.00
Hold$20.001,318.44% Upside
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest GNPX, CLGN, SKYE, and MTVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/19/2026
MetaVia Inc. stock logo
MTVA
MetaVia
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
10/15/2026
Genprex stock logo
GNPX
Genprex
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
9/4/2026
CollPlant Biotechnologies Ltd. Sponsored ADR stock logo
CLGN
CollPlant Biotechnologies
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
8/27/2026
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 10/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CollPlant Biotechnologies Ltd. Sponsored ADR stock logo
CLGN
CollPlant Biotechnologies
$2.37M2.92N/AN/A$4.76 per share0.77
Genprex stock logo
GNPX
Genprex
N/AN/AN/AN/A$53.16 per shareN/A
MetaVia Inc. stock logo
MTVA
MetaVia
N/AN/AN/AN/A$2.31 per shareN/A
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/AN/AN/AN/A$5.00 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CollPlant Biotechnologies Ltd. Sponsored ADR stock logo
CLGN
CollPlant Biotechnologies
-$11.49M-$13.59N/AN/AN/A-678.37%-298.21%-167.83%12/2/2026 (Estimated)
Genprex stock logo
GNPX
Genprex
-$16.23M-$133.36N/AN/AN/AN/A-163.12%-128.98%12/2/2026 (Estimated)
MetaVia Inc. stock logo
MTVA
MetaVia
-$12.97M-$3.23N/AN/AN/AN/A-209.67%-107.91%11/5/2026 (Estimated)
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-$55.92M-$10.16N/AN/AN/AN/A-329.08%-201.79%N/A

Latest GNPX, CLGN, SKYE, and MTVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
MetaVia Inc. stock logo
MTVA
MetaVia
-$0.7333N/AN/AN/AN/AN/A
9/30/2026Q2 2026
CollPlant Biotechnologies Ltd. Sponsored ADR stock logo
CLGN
CollPlant Biotechnologies
-$2.45-$1.89+$0.56-$1.89$0.48 million$0.11 million
8/14/2026Q2 2026
Genprex stock logo
GNPX
Genprex
N/A-$9.40N/A-$9.40N/AN/A
8/14/2026Q2 2026
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-$0.29-$0.27+$0.02-$2.4550N/AN/A
8/6/2026Q2 2026
MetaVia Inc. stock logo
MTVA
MetaVia
-$0.82-$0.90-$0.08-$0.90N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CollPlant Biotechnologies Ltd. Sponsored ADR stock logo
CLGN
CollPlant Biotechnologies
N/AN/AN/AN/AN/A
Genprex stock logo
GNPX
Genprex
N/AN/AN/AN/AN/A
MetaVia Inc. stock logo
MTVA
MetaVia
N/AN/AN/AN/AN/A
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CollPlant Biotechnologies Ltd. Sponsored ADR stock logo
CLGN
CollPlant Biotechnologies
N/A
1.57
1.35
Genprex stock logo
GNPX
Genprex
N/A
6.76
6.76
MetaVia Inc. stock logo
MTVA
MetaVia
N/A
2.06
2.06
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/A
0.95
0.95

Institutional Ownership

CompanyInstitutional Ownership
CollPlant Biotechnologies Ltd. Sponsored ADR stock logo
CLGN
CollPlant Biotechnologies
21.69%
Genprex stock logo
GNPX
Genprex
14.05%
MetaVia Inc. stock logo
MTVA
MetaVia
1.37%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
21.09%

Insider Ownership

CompanyInsider Ownership
CollPlant Biotechnologies Ltd. Sponsored ADR stock logo
CLGN
CollPlant Biotechnologies
9.60%
Genprex stock logo
GNPX
Genprex
0.25%
MetaVia Inc. stock logo
MTVA
MetaVia
0.60%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
6.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
CollPlant Biotechnologies Ltd. Sponsored ADR stock logo
CLGN
CollPlant Biotechnologies
391.89 million1.71 millionOptionable
Genprex stock logo
GNPX
Genprex
13820,000818,000No Data
MetaVia Inc. stock logo
MTVA
MetaVia
85.16 million5.13 millionN/A
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
124.43 million4.15 millionOptionable

Recent News About These Companies

Skye Bioscience (NASDAQ:SKYE) Shares Climb 1.3% - Time to Buy?
October 16, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31124212
Il direttore di Skye Bioscience Andrew Schwab vende azioni per $239.555
September 25, 2026  |  it.investing.comhttps://it.investing.com/news/insider-trading-news/il-direttore-di-skye-bioscience-andrew-schwab-vende-azioni-per-239555-93CH-3562277
Skye Bioscience (NASDAQ:SKYE) Stock: Insider Andrew Schwab Sells 28,700 Shares
September 25, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-skye-insider-buying-and-selling-2026-09-25/
5Am Partners Vii, Llc Sells 33,892 Shares of Skye Bioscience (NASDAQ:SKYE) Stock
September 19, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-skye-insider-buying-and-selling-2026-09-19/
Skye Bioscience average analyst price target raised 10.29% to $61.20
September 15, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/skye-bioscience-average-analyst-price-target-raised-10-29-to-61-20/ar-AA2ch1eV
Skye Bioscience (SKYE) shares rise 6% after hours: Here's what's driving the move
August 26, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/skye-bioscience-skye-shares-rise-6-after-hours-heres-whats-driving-the-move/ar-AA2aWZZE
Skye Bioscience (NASDAQ:SKYE) Director Sells 68,140 Shares
August 21, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-skye-insider-buying-and-selling-2026-08-21/
Skye Bioscience, Inc. (SKYE) M&A Call Prepared Remarks Transcript
August 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4936945-skye-bioscience-inc-skye-m-and-a-call-prepared-remarks-transcript
Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings
August 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/14/3345392/0/en/skye-bioscience-and-redx-pharma-announce-transaction-agreement-and-125-million-in-financings.html
Pomerantz LLP Commences Class Action Against Skye Bioscience, Inc. – SKYE
July 12, 2026  |  natlawreview.comN
Cadrenal Therapeutics Names Sharp Interim CFO
June 29, 2026  |  marketwatch.comhttps://www.marketwatch.com/story/cadrenal-therapeutics-names-sharp-interim-cfo-d989c809
Skye Bioscience Expands Authorized Shares After Shareholder Approval
May 29, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/skye-bioscience-expands-authorized-shares-after-shareholder-approval?utm_source=marketbeat.com&utm_medium=referral
Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1
May 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/20/3298335/0/en/skye-announces-cohort-review-committee-approved-opening-of-cohort-2-based-on-favorable-safety-data-from-first-four-participants-treated-in-cohort-1.html
Skye Bioscience (SKYE) price target decreased by 11.48% to 7.87
May 14, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/skye-bioscience-skye-price-target-decreased-by-1148-to-787/ar-AA23efXu
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Coherus Biosciences (CHRS), Moderna (MRNA) and Skye Bioscience (SKYE)
May 14, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MRNA/pressreleases/1894362/analysts-opinions-are-mixed-on-these-healthcare-stocks-coherus-biosciences-chrs-moderna-mrna-and-skye-bioscience-skye/
Skye Bioscience, Inc.: Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
May 14, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68466082-skye-bioscience-inc-skye-bioscience-reports-first-quarter-2026-financial-results-and-business-update-399.htm
Pomerantz LLP Files Investor Lawsuit Against Skye Bioscience, Inc. – SKYE
May 13, 2026  |  natlawreview.comN
Skye Bioscience Initiates CBeyond™ Expansion Study (Part C) with Planned Review on May 18, 2026
May 12, 2026  |  quiverquant.comQ
UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
May 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/12/3293281/0/en/update-skye-bioscience-reports-first-quarter-2026-financial-results-and-business-update.html
Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
May 11, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/11/3292287/0/en/skye-bioscience-reports-first-quarter-2026-financial-results-and-business-update.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

CollPlant Biotechnologies stock logo

CollPlant Biotechnologies NASDAQ:CLGN

$3.66 +0.04 (+1.10%)
As of 10:58 AM Eastern
This is a fair market value price provided by Massive. Learn more.

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.

Genprex stock logo

Genprex NASDAQ:GNPX

$1.86 -0.12 (-5.81%)
As of 11:03 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

MetaVia stock logo

MetaVia NASDAQ:MTVA

$1.41 +0.02 (+1.44%)
As of 10:58 AM Eastern
This is a fair market value price provided by Massive. Learn more.

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.

Skye Bioscience stock logo

Skye Bioscience NASDAQ:SKYE

$1.59 -0.03 (-2.10%)
As of 11:05 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas